SG
NVO

Societe Generale’s Novo Nordisk NVO Stock Holding History

Societe Generale’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$1.33M Buy
+49,500
New +$1.36M 0.01% 1113

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Societe Generale's NVO Position: Q2 2016 in Review

Societe Generale opened a new position in Novo Nordisk (NVO) in Q2 2016: 49,500 shares worth $1.33M. The stake represents 0.01% of the portfolio and ranks #1113 among its holdings.

529 funds tracked by Wall St. Rank hold NVO as of Q2 2016.

  • Societe Generale held 49,500 shares of Novo Nordisk worth $1.33M as of Q2 2016.
  • Novo Nordisk was a new Societe Generale position in Q2 2016.
  • Novo Nordisk made up 0.01% of Societe Generale's portfolio in Q2 2016, its #1113 holding.
  • 529 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.